Advertisement

Evaluation of Epstein-Barr Virus Serologic Analysis in North American Patients with Nasopharyngeal Carcinoma and in Comparison Groups

  • H. Bryan NeelIII
  • Gary R. Pearson
  • William F. Taylor
Part of the Developments in Medical Virology book series (DIMV, volume 1)

Summary

This prospective cooperative study was initiated in 1978 to determine the value of serologic tests related to Epstein-Barr virus (EBV), including the antibody response to the EBV membrane antigen as measured by the antibody-dependent cellular cytotoxicity (ADCC) assay, in North American patients with different histopathologic types of nasopharyngeal carcinoma (NPC). Serologic testing is a useful diagnostic aid for patients with NPC, particularly those in whom the tumors are small and submucosal (difficult to see or occult). A large body of clinical evidence, histopathologic data, and more recently immunologic studies supports the concept that carcinomas of the nasopharynx constitute two distinct diseases. Today, these are classified as WHO type 1 tumors and combined WHO types 2 and 3 tumors. The ADCC titers obtained at diagnosis often predict the clinical course of patients with WHO types 2 and 3 NPC regardless of the stage of the disease. A low ADCC titer at diagnosis portends a poor prognosis, and the determination of antibody titers identifies patients in whom recurrent disease is likely to develop after conventional irradiation therapy.

This prospective cooperative study was initiated in 1978 to determine the value of serologic tests related to Epstein-Barr virus (EBV), including the antibody response to the EBV membrane antigen as measured by the antibody- dependent cellular cytotoxicity (ADCC) assay, in North American patients with different histopathologic types of nasopharyngeal carcinoma (NPC). It involves several institutions in the United States to provide a sufficient number of patients—mostly Caucasians—from different geographic locations and diverse ethnic backgrounds (Neel et al., 1980, 1981A, 1983, 1984, in press; Pearson et al., 1983). Other studies, primarily in Chinese patients, have found potential value for most of the antibody responses (Henle and Henle, 1966, 1976; Henle et al., 1970, 1971, 1977; Pearson et al., 1971; Ho et al., 1978; Naegele et al., 1982; Sundar et al., 1982; Ringborg et al., 1983).

This report explores the data on the NPC patients and on controls consisting of normal blood donors, patients with squamous cell carcinoma elsewhere in the head and neck, and patients with benign diseases commonly seen in an otorhinolaryngologic practice.

Keywords

Squamous Cell Carcinoma Chronic Lymphocytic Leukemia Nasopharyngeal Carcinoma Actuarial Survival Histopathologic Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Joint Committee for Cancer Staging and End-Results Reporting: Manual for Staging of Cancer 1977. Published by the American Joint Committee, 55 East Erie Street, Chicago, IL 60611 (1977).Google Scholar
  2. Bertram, G., Pearson, G.R., Faggioni, A., Krueger, G.R.F., Sesterhenn, K., Ablashi, D.V., and Levine, P.H., A long-term study of EBV and non-EBV related tests and their correlation with the clinical course of nasopharyngeal carcinoma. In: U. Prasad, D.V. Ablashi, P.H. Levine, and G.R. Pearson (ed.), Proceedings of the Fourth International Symposium on Nasopharyngeal Carcinoma, pp. 115–124, University of Malaya Press, Kuala Lumpur (1983).Google Scholar
  3. Henle, G. and Henle, W., Immunofluorescence in cells derived from Burkitt’s lymphoma. J. Bacteriol., 91, 1248–1256 (1966).PubMedGoogle Scholar
  4. Henle, G. and Henle, W., Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer, 17, 1–7 (1976).PubMedCrossRefGoogle Scholar
  5. Henle, G., Henle, W., and Klein, G., Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int. J. Cancer, 8, 272–282 (1971).PubMedCrossRefGoogle Scholar
  6. Henle, W., Henle, G., Zajac, B.A., Pearson, G., Waubke, R., and Scriba, M., Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science, 169, 188–190 (1970).PubMedCrossRefGoogle Scholar
  7. Henle, W., Ho, J.H.C., Henle, G., Chau, J.C.W., and Kwan, H.C., Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int. J. Cancer, 20, 663–672 (1977).PubMedCrossRefGoogle Scholar
  8. Ho, H.C., Ng, M.H., and Kwan, H.C., Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br. J. Cancer, 37, 356–362 (1978).PubMedCrossRefGoogle Scholar
  9. Ho, J.H.C., Stage classification of nasopharyngeal carcinoma: a review. In: G. de-Thé and Y. Ito (ed.), Nasopharyngeal Carcinoma: Etiology and Control, pp. 99–113, International Agency for Research on Cancer, Lyon, France (1978).Google Scholar
  10. Kaplan, E.L. and Meier, P., Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457–481 (1958).CrossRefGoogle Scholar
  11. Mathew, G.D., Qualtiere, L.F., Neel, H.B., III, and Pearson, G.R., Immunoglobulin A antibody to Epstein-Barr viral antigens and prognosis in nasopharyngeal carcinoma. Otolaryngol. Head Neck Surg., 88, 52–57 (1980).PubMedGoogle Scholar
  12. Mathew, G.D., Qualtiere, L.F., Neel, H.B., III, and Pearson, G.R., IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int. J. Cancer, 27, 175–180 (1981).PubMedCrossRefGoogle Scholar
  13. Naegele, R.F., Champion, J., Murphy, S., Henle, G., and Henle, W., Nasopharyngeal carcinoma in American children: Epstein-Barr virus-specific antibody titers and prognosis. Int. J. Cancer, 29, 209–212 (1982).PubMedCrossRefGoogle Scholar
  14. Neel, H.B., III, Pearson, G.R., and Taylor, W.F., Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Ann. Otol. Rhinol. Laryngol., 93, 477–482 (1984).PubMedGoogle Scholar
  15. Neel, H.B., III, Pearson, G.R., and Taylor, W.F., Antibody- dependent cellular cytotoxicity: relation to stage and disease course in North American patients with nasopharyngeal carcinoma. Arch. Otolaryngol, (in press).Google Scholar
  16. Neel, H.B., III, Pearson, G.R., Weiland, L.H., Taylor, W.F., and Goepfert, H.H., Immunologic detection of occult primary cancer of the head and neck. Otolaryngol. Head Neck Surg., 89, 230–234 (1981A).Google Scholar
  17. Neel, H.B., III, Pearson, G.R., Weiland, L.H., Taylor, W.F., Goepfert, H.H., Pilch, B.Z., Goodman, M., Lanier, A.P., Huang, A.T., Hyams, V.J., Levine, P.H., Henle, G., and Henle W., Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. Otolaryngol. Head Neck Surg., 91, 255–262 (1983).PubMedGoogle Scholar
  18. Neel, H.B., III, Pearson, G.R., Weiland, L.H., Taylor, W.F., Goepfert, H.H., Pilch, B.Z., Lanier, A.P., Huang, A.T., Hyams, V.J., Levine, P.H., Henle, G., and Henle, W., Anti-EBV serologic tests for nasopharyngeal carcinoma. Laryngoscope, 90, 1981–1990 (1980).PubMedCrossRefGoogle Scholar
  19. Neel, H.B., III, Taylor, W.F., Pearson, G.R., and Weiland, L.H., Clinical staging of patients with nasopharyngeal carcinoma. In: E. Grundmann, G. Krueger, and D. Ablashi (ed.), Cancer Campaign, Vol. 5, pp. 73–79, Gustav Fischer Verlag, Stuttgart (1981B).Google Scholar
  20. Pearson, G.R., Henle, G., and Henle, W., Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines. J. Natl. Cancer Inst., 46, 1243–1250 (1971).PubMedGoogle Scholar
  21. Pearson, G.R., Johansson, B., and Klein, G., Antibody- dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma. Int. J. Cancer, 22, 120–125 (1978).PubMedCrossRefGoogle Scholar
  22. Pearson, G.R. and Orr, T.W., Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. J. Natl. Cancer Inst., 56, 485–488 (1976).PubMedGoogle Scholar
  23. Pearson, G.R., Weiland, L.H., Neel, H.B., III, Taylor, W., Earle, J., Mulroney, S.E., Goepfert, H., Lanier, A., Talvot, M.L., Pilch, B., Goodman, M., Huang, A., Levine, P.H., Hyams, V., Moran, E., Henle, G., and Henle, W., Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer, 51, 260–268 (1983).PubMedCrossRefGoogle Scholar
  24. Qualtiere, L.F., Chase, R., and Pearson, G.R., Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein. J. Immunol., 129, 814–818 (1982).PubMedGoogle Scholar
  25. Ringborg, U., Henle, W., Henle, G., Ingimarsson, S., Klein, G., Silfuersward, C., and Strander, H., Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck. Cancer, 52, 1237–1243 (1983).PubMedCrossRefGoogle Scholar
  26. Shanmugaratnam, K. and Sobin, L., Histological Typing of Upper Respiratory Tract Tumours. No. 19, World Health Organization, Geneva, Switzerland, pp. 32–33 (1978).Google Scholar
  27. Sundar, S.K., Ablashi, D.V., Kamaraju, L.S., Levine, P.H., Faggioni, A., Armstrong, G.R., Pearson, G.R., Krueger, G.R., Hewetson, J.F., Bertram, G., Sesterhenn, and Menezes, J., Sera from patients with undifferentiated nasopharyngeal carcinoma contain a factor which abrogates specific Epstein-Barr virus antigen-induced lymphocyte response. Int. J. Cancer, 29, 407–412 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • H. Bryan NeelIII
    • 1
  • Gary R. Pearson
    • 1
  • William F. Taylor
    • 1
  1. 1.Mayo Clinic and Mayo FoundationRochesterUSA

Personalised recommendations